title: Outcome of acute promyelocytic leukemia treated with all trans retinoic acid and chemotherapy in elderly patients: the European group experience.
abstract: We analyzed the outcome of patients aged more than 60 included in a multicenter trial in newly diagnosed acute promyelocytic leukemia (APL93 trial), which tested the role of early addition of chemotherapy to all trans retinoic acid (ATRA) and of maintenance with ATRA and/or low-dose chemotherapy. In total, 129/533 (24.2%) patients included in this trial were older than 60. The CR rate was 86% in patients older than 60 as compared to 94.5% in younger patients (P=0.0014), due to a higher incidence of early deaths in elderly patients. The 4-year incidence of relapse was 15.6% in adults older than 60 and 23.2% in younger adults although most elderly patients received less intensive consolidation chemotherapy. However, 18.6% of the patients older than 60 years who achieved CR died in CR, mainly from sepsis during consolidation course or maintenance treatment, as compared to 5.7% of younger adults (P<0.001). Thus, overall 4-year survival of elderly patients was 57.8% as compared to 78% in younger adults (P<0.0001). APL in elderly patients appears as sensitive to ATRA-Chemotherapy based regimen as in younger adults. Less favorable outcome is mainly due to an increase of early deaths and to toxicity of consolidation treatment, strongly suggesting a beneficial role for less intensive consolidation chemotherapy and possibly introduction of arsenic derivates in the treatment of APL in the elderly.
authors.affiliation: Service d'hématologie clinique/Hôpital Avicenne, Paris XIII University, Bobigny, France.
authors.forename: L
authors.initials: L
authors.lastname: Ades
authors.forename: S
authors.initials: S
authors.lastname: Chevret
authors.forename: S
authors.initials: S
authors.lastname: De Botton
authors.forename: X
authors.initials: X
authors.lastname: Thomas
authors.forename: H
authors.initials: H
authors.lastname: Dombret
authors.forename: B
authors.initials: B
authors.lastname: Beve
authors.forename: M
authors.initials: M
authors.lastname: Sanz
authors.forename: A
authors.initials: A
authors.lastname: Guerci
authors.forename: J S
authors.initials: JS
authors.lastname: Miguel
authors.forename: J
authors.initials: J
authors.lastname: Dela Serna
authors.forename: C
authors.initials: C
authors.lastname: Garo
authors.forename: A M
authors.initials: AM
authors.lastname: Stoppa
authors.forename: O
authors.initials: O
authors.lastname: Reman
authors.forename: A
authors.initials: A
authors.lastname: Stamatoulas
authors.forename: M
authors.initials: M
authors.lastname: Fey
authors.forename: J Y
authors.initials: JY
authors.lastname: Cahn
authors.forename: J J
authors.initials: JJ
authors.lastname: Sotto
authors.forename: J H
authors.initials: JH
authors.lastname: Bourhis
authors.forename: A
authors.initials: A
authors.lastname: Parry
authors.forename: C
authors.initials: C
authors.lastname: Chomienne
authors.forename: L
authors.initials: L
authors.lastname: Degos
authors.forename: P
authors.initials: P
authors.lastname: Fenaux
mesh_terms: D000293:Adolescent; D000328:Adult; D000367:Age Factors; D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D005060:Europe; D005260:Female; D006801:Humans; D015473:Leukemia, Promyelocytic, Acute / Q000188:drug therapy* / Q000401:mortality; D008297:Male; D008875:Middle Aged; D012008:Recurrence; D016019:Survival Analysis; D016896:Treatment Outcome; D014212:Tretinoin / Q000627:therapeutic use*
chemical_list: D000970:Antineoplastic Agents; D014212:Tretinoin